Spondyloarthritis & psoriatic arthritis
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network
Authors' conclusion
In this European real-world study of patients with axSpA initiating SEC, predictors of achieving LDA by ASDAS-CRP and BASDAI at 6 months and remaining on treatment at 12 months included both clinical, patient-reported, and lifestyle factors, underscoring the complex mechanisms of real-world drug effectiveness.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) initiating secukinumab in routine care, 11 European registries (EuroSpA), with 6-month ASDAS-CRP and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) datapooled cohort
- Participants
- 1,174 patients
- Outcome
- Baseline predictors of LDA by ASDAS-CRP and BASDAI, and of treatment continuation
- Follow-up
- LDA at 6 months; continuation at 12 months
Methodological detailsmulticentre, 11 European registries, routine care, logistic regression on multiply imputed baseline data
- Multicentre
- 11 European registries
- Routine care
- Logistic regression on multiply imputed baseline data
Main finding
As reported in the abstract
Predictors of LDA (5 of 19 variables mutually predictive for ASDAS-CRP and BASDAI LDA) · 6 months
- Higher PGA score
- Noncurrent smoking
- No prior b/tsDMARD exposure
- Lower HAQ scores
- Lower BASDAI scores
Observational data: associations, not effects.
Further findings
Predictors of ASDAS-CRP low disease activity (LDA) only · 6 months
- Radiographic axSpA associated with ASDAS-CRP LDA
- CRP ≤ 10 mg/L associated with ASDAS-CRP LDA
Predictors of BASDAI LDA only · 6 months
- HLA-B27 positivity associated with BASDAI LDA
- History of psoriasis associated with BASDAI LDA
Predictors of treatment continuation · 12 months
- Earlier secukinumab (SEC) initiation (2015-2017) associated with treatment continuation
Original publication
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network. J Rheumatol. Published 1 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →